A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
Seagen Inc.
Seagen Inc.
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
Aileron Therapeutics, Inc.
Dizal Pharmaceuticals
Ohio State University Comprehensive Cancer Center
Boryung Pharmaceutical Co., Ltd
The Lymphoma Academic Research Organisation
Dizal Pharmaceuticals
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Bristol-Myers Squibb
Dizal Pharmaceuticals
Nanjing Zenshine Pharmaceuticals
Affimed GmbH
BeiGene
Takeda
HUYABIO International, LLC.
AstraZeneca
Kura Oncology, Inc.
Kyowa Kirin Co., Ltd.
Washington University School of Medicine
Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd.
Innate Pharma
University of Michigan Rogel Cancer Center
University Hospital Southampton NHS Foundation Trust
Solasia Pharma K.K.
Eisai Inc.
Celgene
Stanford University
University of Nebraska
University of Nebraska
University of Nebraska
Weill Medical College of Cornell University
Canadian Cancer Trials Group
Therapeutic Advances in Childhood Leukemia Consortium
Karyopharm Therapeutics Inc
National Institutes of Health Clinical Center (CC)
The Lymphoma Academic Research Organisation
Columbia University
Chonnam National University Hospital
Mayo Clinic
Peter MacCallum Cancer Centre, Australia
University of Birmingham
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Spectrum Pharmaceuticals, Inc
AbbVie
Acrotech Biopharma Inc.
Eisai Inc.